Does Diabetes Drug Rosiglitazone Raise Risk of Heart Ailments?
3.8 million prescriptions of the type 2 diabetes drug rosiglitazone is given in the United States annually. The drug is believed to raise the complications of heart as its side effect. Its usage in the Europe has been banned from last year.
To gain clarity in this issue, British and American scientists carried out an analysis. The results of their study were published in the March 17, 2011 issue of the British Medical Journal.
They analyzed results of 16 research studies carried out on 810,000 patients who took the drugs rosiglitazone and pioglitazone. Both the drugs are prescribed for type 2 diabetes treatment in large numbers.
The researchers found that the former drug indeed was associated with rise in the heart ailments. The risks of heart failure, heart attack and death stood at 23 percent, 16 percent and 14 percent respectively.
The experts believe that collective collaboration between the federal officials, health care professionals and patients can only address the issue in all its complexities.